GlassScriptPhysician profile
Abinav Baweja
NPI 1770961575
$2,548.53
in general payments reported to CMS, 2019-2025
36 companies · $53.20 in 2025
The $53.20 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $96.76 · 2022: $516 · 2023: $1,858 · 2024: $25.23 · 2025: $53.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $183.97 | 2022-2023 | Tukysa, Padcev |
| Janssen Biotech, INC. | $179.11 | 2022-2023 | Darzalex, Imbruvica, Rybrevant |
| Merck Sharp & Dohme LLC | $158.67 | 2023 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $152.17 | 2022-2023 | Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $141.25 | 2022-2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $127.40 | 2023 | Opdivo |
| Exelixis INC. | $127.06 | 2020-2023 | Cabometyx |
| Genzyme Corporation | $122.29 | 2022-2023 | |
| Pfizer INC. | $115.86 | 2022-2023 | |
| Amgen INC. | $112.62 | 2022-2023 | Lumakras |
| Taiho Oncology, INC. | $98.69 | 2022-2023 | |
| Genentech USA, INC. | $92.61 | 2023 | Phesgo, Perjeta, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $88.29 | 2022-2023 | Imfinzi, Calquence, Enhertu |
| Sanofi-Aventis U.S. LLC | $81.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $78.40 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $57.45 | 2023 | Yescarta |
| Alnylam Pharmaceuticals INC. | $57.06 | 2023-2025 | Givlaari |
| Astellas Pharma US INC | $50.13 | 2023 | Padcev |
| Pharmacyclics LLC, An Abbvie Company | $48.24 | 2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $45.58 | 2022-2023 | |
| Emd Serono, INC. | $43.46 | 2023 | Tepmetko, Bavencio |
| Eisai INC. | $35.94 | 2022-2023 | |
| Glaxosmithkline, LLC. | $33.76 | 2025 | Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $29.50 | 2023 | Ninlaro, Vpriv |
| Sumitomo Pharma America, INC. | $28.00 | 2023 | Orgovyx |
| Octapharma USA, INC. | $27.16 | 2023 | Panzyga |
| Gilead Sciences, INC. | $26.82 | 2023 | Trodelvy |
| Tactile Systems Technology INC | $26.09 | 2023 | Flexitouch Plus, Entre Plus |
| Immunogen, INC. | $24.40 | 2023 | Elahere |
| Mirati Therapeutics, INC. | $24.03 | 2023 | Krazati |
| Array Biopharma INC | $23.75 | 2023 | Braftovi, Mektovi |
| Apellis Pharmaceuticals, INC. | $23.08 | 2023 | |
| Foundation Medicine, INC. | $22.69 | 2023 | |
| Genmab U.S., INC. | $21.84 | 2023 | Epkinly |
| Incyte Corporation | $21.67 | 2023 | Jakafi |
| Recordati_rare_diseases_inc. | $17.50 | 2023 | Sylvant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abinav Baweja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.